ClinConnect ClinConnect Logo
Search / Trial NCT06628297

Comparison of Differencens in VO2-max, Perfusion of the Heart and Brain and Cognitive Performance Between Patients with Type 2 Diabetes and Healthy Age Matched Controls.

Launched by UNIVERSITY HOSPITAL BISPEBJERG AND FREDERIKSBERG · Oct 2, 2024

Trial Information

Current as of August 29, 2025

Not yet recruiting

Keywords

Microvascular Disease Microvascular Complications Of The Heart Microvascular Complications Of The Brain Diabetes Type 2 Dementia Microvascular Disease Patophysiology

ClinConnect Summary

This clinical trial is investigating how the heart and brain function in patients with type 2 diabetes compared to healthy individuals of the same age. Specifically, the researchers want to understand the differences in how well the heart and brain receive blood (which is important for their health), how well patients can exercise, and how this affects their thinking abilities. They believe that individuals with diabetes may have reduced blood flow to both the heart and brain, which could lead to problems with memory and overall brain function.

To participate in this study, you need to be over 60 years old and either have type 2 diabetes or be a healthy individual without diabetes. If you have diabetes, you should have been diagnosed for more than five years or have certain related health issues, and you need to be able to speak and understand Danish. The study will involve assessments of heart and brain health, and participants may also be involved in activities to see if exercise or diet can help improve their cognitive function. It's important to note that some individuals with certain heart or brain conditions, or those who exercise intensely, may not be eligible to join the trial.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria for the patients with type 2 diabetes:
  • Diabetes type II diagnose with one of the following:
  • Duration over 5 years
  • Moderate microalbuminuria
  • Non-proliferative diabetic retinopathy
  • Speaks and understands Danish (required for reliable cognitive testing)
  • Able to provide informed and written consent
  • Exclusion Criteria or the patients with type 2 diabetes:
  • Moderate to high intensity training \>1 times/week.
  • Previous AMI, atrial fibrillation, significant cardiac valve disease, HFrEF (LVEF \<45%), asthma.
  • Previous stroke or significant neurological disease including cognitive dysfunction.
  • Ongoing depression.
  • Hypothyroidism
  • Unable or unwilling to participate in training, e.g., due to injury, arthrosis or lung disease.
  • Inclusion Criteria for the healthy age-matched controls:
  • Age \> 60 years
  • No diagnosis of T2D according to WHO\'s criteria.
  • Speaks and understands Danish (required for reliable cognitive testing)
  • Able to provide informed and written consent
  • Exclusion Criteria for the healthy age-matched controls:
  • Moderate to high intensity training \>2 times/week.
  • Previous AMI, atrial fibrillation, significant cardiac valve disease, HFrEF (LVEF \<45%), asthma.
  • Previous stroke or significant neurological disease including cognitive dysfunction.
  • Ongoing depression.
  • Hypothyroidism
  • Unable or unwilling to participate in training, e.g., due to injury, arthrosis or lung disease.

About University Hospital Bispebjerg And Frederiksberg

University Hospital Bispebjerg and Frederiksberg is a leading academic medical institution in Denmark, dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital integrates cutting-edge scientific inquiry with patient-centered care, fostering collaboration among multidisciplinary teams of healthcare professionals and researchers. The institution emphasizes a strong commitment to ethical standards and regulatory compliance, ensuring that all trials are designed to enhance medical knowledge and improve patient outcomes. With a focus on a wide range of therapeutic areas, University Hospital Bispebjerg and Frederiksberg strives to contribute significantly to the global medical community and the advancement of evidence-based practice.

Locations

Copenhagen, , Denmark

Patients applied

0 patients applied

Trial Officials

Thomas EHJ Primary Investigator, Medical Doctor

Principal Investigator

University Hospital Bispebjerg and Frederiksberg

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported